Biomarker Testing in Non-Small Cell Lung Cancer: Optimal Care Coordination Starts with You
Tue, Aug 10
|Zoom
Join the Boston Chapter for a fun virtual discussion surrounding Biomarker Testing!
Time & Location
Aug 10, 2021, 6:00 PM – 7:00 PM
Zoom
Guests
About The Event
Length of session: 1 hourÂ
Agenda:
Introductions - Welcoming Everyone to this Virtual Activity (5min)
Video Viewing with Discussion (55 min)
Questions throughout include the following:
o Have you found any of these targets in your patients with lung cancer?
o Did any of these results surprise you?
o How do you coordinate out-of-state or different rules at different institutions?Â
o How do you know if biomarker testing was initiated?Â
o What is your process for ordering and retrieving biomarker results?
*Think of a patient in your practice that has a certain biomarker including a PD-L1 expression this may apply to. Think about how you can use this tool in educating the patient on how biomarker results guide their treatment selection.
Additional Resources available:
- Glad You Asked video (~5 min): What is the role of the KRAS biomarker in NSCLC?Â
- o Listen to Beth Sandy MSN, CRNP, Thoracic Oncology Nurse Practitioner talk about the role of the KRAS biomarker in non-small cell lung cancer. She will explain how this biomarker drives cancer growth, the different types of variants, and introduce KRAS inhibiting targeted therapies that are in clinical trials.Â
- • Podcast: Episode 157: Biomarker Testing Improves Outcomes for Patients With Non-Small Cell Lung Cancer Here is a link to the podcastÂ
- o • Biomarker Testing in Non-Small Cell Lung Cancer Discussion Tool and Facilitator Guide o Explaining the complex biomarker testing process to your patients can be made simple by utilizing the Biomarker Testing in Non-Small Cell Lung Cancer Discussion Tool to guide this conversation with your patients. It provides patient friendly language to describe biomarker testing and the why, when, and how of the process. It gives the patient space to write notes and capture their cancer’s biomarkers. Also, available for download is the facilitator guide which describes two models you may use when reviewing the discussion tool with a group of nurses.